**Table S1. Patient demographics and clinical characteristics informed by participating neurologists, overall and by clinical course**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Overall**  | **Monophasic**  | **Relapsing** |
| **Age in years at survey completion** |  |  |  |
| **Total number of patients, n**Mean (SD)Median (Q1,Q2)Min; max | **268**36.4 (11.1)36.0 (28.0; 43.0)18.0; 75.0 | **178**35.6 (10.9)35.0 (27.8; 42.0)18.0; 75.0 | **90**38.0 (11.3)38.0 (30.0; 45.0)18.0; 73.0 |
| **Age in years at diagnosis** |  |  |  |
| **Total number of patients, n**Mean (SD)Median (Q1,Q2)Min; max | **236**33.6 (10.6)33.3 (25.6; 40.1)16.0; 68.0 | **161**33.5 (10.4)33.8 (25.2; 40.3)16.0; 64.0 | **75**33.8 (11.1)32.8 (26.5; 39.8)17.0; 68.0 |
| **Age in years at symptom onset** |  |  |  |
| **Total number of patients, n**Mean (SD)Median (Q1,Q2)Min; max | **223**32.8 (10.2)32.5 (24.6; 39.7)12.0; 66.0 | **155**33.0 (10.3)32.5 (24.6; 40.2)16.0; 64.0 | **68**32.3 (10.3)32.5 (25.0; 38.9)17.0; 68.0 |
| **Sex** |  |  |  |
| **Total number of patients, n (%)**FemaleMale | **268 (100)**173 (64.6)95 (35.4) | **178 (100)**115 (64.6)63 (35.4) | **90 (100)**58 (64.4)32 (35.6) |
| **Ethnicity1** |  |  |  |
| **Total number of patients, n (%)**White/CaucasianHispanic/LatinoAfrican AmericanOther | **268 (100)**229 (85.4)12 (4.5)11 (4.1)16 (6.0) | **178 (100**148 (83.1)9 (5.1)7 (3.9)14 (7.9) | **90 (100)**81 (90.0)3 (3.3)4 (4.4)2 (2.2) |
| **Comorbidities** |  |  |  |
| **Total number of patients, n (%)**None reportedAt least one reported | **268 (100)**171 (63.8)97 (36.2) | **178 (100)**118 (66.3)60 (33.7) | **90 (100)**53 (58.9)37 (41.1) |
| **Comorbidities among patients that reported at least one1,2** |  |  |  |
| **Total number of patients, n (%)**DepressionGeneralized anxietyDiabetes without chronic complications | **97 (100)**39 (40.2)36 (37.1)18 (18.6) | **60 (100)**21 (35.0)20 (33.3)13 (21.7) | **37 (100)**18 (48.6)16 (43.2)5 (<1.0) |

Abbreviations: EU5, France, Germany, Italy, Spain, and United Kingdom; IQR, interquartile range; MOGAD, myelin-oligodendrocyte glycoprotein antibody-associated disease; n, number of PRF responses; PRF, patient record form; SD, standard deviation.

1Categories are not mutually exclusive.

2Comorbidities with a prevalence in the total sample <2% not reported.

**Table S2.** **Patient demographics and clinical characteristics self-reported by patients with MOGAD, reported overall and by geography**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Overall** | **EU5** | **US** |
| **Age in years at survey completion****Total number of respondents, n**Mean (SD)Median (Q1, Q3)Min; max | **66**33.6 (10.8)34.0 (22.8; 41.0)18.0; 65.0 | **56**33.0 (11.1)32.0 (22.0; 41.0)18.0; 65.0 | **7**38.4 (4.0)39.0 (35.0; 41.0)33.0; 45.0 |
| **Sex** **Total number of respondents, n (%)**MaleFemale | **66 (100)**27 (40.9)39 (59.1) | **56 (100)**25 (42.4)34 (57.6) | **7 (100)**2 (28.6)5 (71.4) |
| **Ethnicity, n (%)1****Total number of respondents, n (%)** White/CaucasianAfrican AmericanHispanic/LatinoOther | **66 (100)**63 (95.5)3 (4.5)0 (0.0)0 (0.0) | **56 (100)**59 (100.0)0 (0.0)0 (0.0)0 (0.0) | **7 (100)**4 (57.1)3 (42.9)0 (0.0)0 (0.0) |
| **Comorbidities****Total number of respondents, n (%)** None reportedAt least one reported**Comorbidities among patients that reported at least one1,2** **Total number of respondents, n (%)** Depression Generalised anxiety Diabetes without chronic complications | **66 (100)**48 (72.7)18 (27.3)**18 (100)**8 (44.4)7 (38.9)3 (16.7) | **56 (100)**45 (76.3)14 (23.7)**14 (100)**7 (50.0)5 (35.7)3 (21.4) | **7 (100)**3 (42.9)4 (57.1)**4 (100)**1 (25.0)2 (50.0)0 (0.0) |
| **Clinical course, n (%)****Total number of respondents, n (%)**MonophasicRelapsing | **66 (100)**36 (54.5)30 (45.5) | **56 (100)**31 (52.5)28 (47.5) | **7 (100)**5 (71.4)2 (28.6) |

Abbreviations: EU5, France, Germany, Italy, Spain, and United Kingdom; Q1, Q3: interquartile range; MOGAD, myelin-oligodendrocyte glycoprotein antibody-associated disease; n, number of PSC responses; PSC, patient self-completion form; SD, standard deviation.

1Categories are not mutually exclusive.

2 Comorbidities with a prevalence in the total sample <2% not reported.

**Table S3. Number and type of tests, scans and assessments performed among patients diagnosed with MOGAD informed by participating neurologists, overall and by geography**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Overall** | **EU5** | **US** |
| **No. tests/scans/assessments conducted to aid MOGAD diagnosis****Total number of patients with available information, n**Mean (SD)Median (Q1, Q3)Min; max | **268** 13.7 (7.0)12.0 (9.0; 19.0)1.0; 36.0 | **213** 14.8 (7.0)14.0 (9.0; 20.0)2.0; 36.0 | **55** 9.6 (5.4)9.0 (5.0; 12.0)1.0; 22.0 |
| **Tests/scans/assessments conducted to aid MOGAD diagnosis1,2****Total number of patients, n (%)**MOG antibody detection (cell-based assay)Brain MRISpinal cord MRI Protein electrophoresis (oligoclonal bands)Physical examinationComplete blood countVisual evoked potentialVisual field testVisual acuity test CSF white cell countBlood white blood countCSF viral PCRBacterial cultureBlood viral PCRSPEPLP opening pressure test Retinal imaging (fundus photography)PCRCSF other PCRbLactateBlood cultureCSF ELISABlood ELISABlood other PCRbHead CT scan | **268 (100.0)**268 (100.0)242 (90.3)234 (87.3)219 (81.7)193 (72.0)168 (62.7)162 (60.4)155 (57.8)150 (56.0)145 (54.1)133 (49.6)109 (40.7)89 (33.2)85 (31.7)80 (29.9)76 (28.4)74 (27.6)68 (25.4)63 (23.5)59 (22.0)57 (21.3)56 (20.9)54 (20.1)46 (17.2)45 (16.8) | **213 (100)**213 (100)195 (91.5)190 (89.2)182 (85.4)160 (75.1)141 (66.2)141 (66.2)132 (62.0)121 (56.8)119 (55.9)118 (55.4)96 (45.1)78 (36.6)71 (33.3)69 (32.4)54 (25.4)65 (30.5)62 (29.1)56 (26.3)53 (24.9)53 (24.9)50 (23.5)51 (23.9)42 (19.7)43 (20.2) | **55 (100)**55 (100)47 (85.5)44 (80.0)37 (67.3)33 (60.0)27 (49.1)21 (38.2)23 (41.8)29 (52.7)26 (47.3)15 (27.3)13 (23.6)11 (20.0)14 (25.5)11 (20.0)22 (40.0)9 (16.4)6 (10.9)7 (12.7)6 (10.9)4 (7.3)6 (10.9)3 (5.5)4 (7.3)2 (3.6) |

Abbreviations: ADEM, acute disseminated encephalomyelitis; AQP-4, aquaporin-4; CSF, cerebrospinal fluid; CT, computed tomography; ELISA, enzyme-linked immunosorbent assay; EU5, France, Germany, Italy, Spain, and United Kingdom; Gd, gadolinium; IgG, immunoglobulin G; LP, lumbar puncture; MOGAD, myelin-oligodendrocyte glycoprotein antibody-associated disease; MRI, magnetic resonance imaging; n, number of PRF responses; PCR, polymerase chain reaction; PRF, patient record form; SPEP, serum protein electrophoresis.

1Categories are not mutually exclusive.

2Tests with a prevalence in the total sample <10% not reported.

Figure S1. Severity of symptoms reported during the initial symptomatic episode among patients with MOGAD, informed by participating neurologists (n=268)

Abbreviations: n, number of PRF responses; PRF, patient record form

No severity data were reported for Babinski sign (n=71) and were therefore excluded from the figure. Symptoms with a prevalence <10% are not presented.